FDA Clears IND for TuHURA's TBS-2025 Anti-VISTA Antibody, Marking Expansion into Blood Cancers

What happened

TuHURA Biosciences announced FDA clearance of its investigational new drug application for TBS-2025, a VISTA-inhibiting monoclonal antibody acquired via the Kineta merger, allowing clinical evaluation in molecularly defined subsets of acute myeloid leukemia and other blood cancers. This marks a concrete development step for the company's second therapeutic pillar, which had previously lacked a defined clinical path in the master report. The clearance diversifies TuHURA's pipeline beyond its lead Phase 3 IFx-2.0 program in Merkel cell carcinoma, but the company remains pre-revenue with only $8.5 million in cash as of June 30, 2025, and a disclosed need for substantial additional funding. The IND approval does not immediately alter the near-term financing risk, as the company must still complete a remaining private placement tranche by end-2025 and manage integration costs from the Kineta merger. Nevertheless, the news provides a tangible catalyst for the anti-VISTA platform, which targets myeloid checkpoint suppression—a mechanism of resistance to existing immunotherapies.

Implication

For investors, the FDA clearance is a modestly positive development that adds optionality to the pipeline, but it also implies additional clinical spending and operational complexity. The near-term investment case remains dominated by the IFx-2.0 Phase 3 trial in MCC, where enrollment and financing are the critical gates. The TBS-2025 program, while now cleared to enter the clinic, will likely require significant capital to advance through dose escalation and efficacy signals, which could strain TuHURA's limited resources. With only $8.5 million in cash as of the last filing and a stated need for substantial funding, dilution risk is elevated regardless of this news. Therefore, the clearance should not materially change the risk profile for existing shareholders until the company demonstrates ability to fund both programs without excessive dilution and shows early clinical signals.

Thesis delta

The master thesis previously emphasized the IFx-2.0 Phase 3 MCC trial as the sole lead value driver, with TBS-2025 viewed as an unclarified bolt-on from the Kineta merger. Today's IND clearance provides the first concrete regulatory milestone for TBS-2025, suggesting the company is actively developing the anti-VISTA program rather than shelving it. This adds a second clinical asset and broadens the strategic narrative, but it does not change the dominant risks of funding and execution; consequently, the thesis shifts from 'single-asset biotech with a side project' to 'dual-asset biotech with even higher cash needs.'